DEFJ converts preferred stock, cementing 83.9% control of Transcode Therapeutics
RNAZ sits 20% above its 52-week low of $3.82.
Summary
DEFJ converted all its preferred stock into common shares, becoming Transcode's 83.9% controlling shareholder. The conversion removes the preferred overhang but concentrates control in one entity.
Key Events · Ownership and Investor Activity · RNAZ
-
Preferred Stock Conversion Executed
On August 3, 2026, DEFJ converted 1,181.3859 shares of Series A Preferred Stock into 11,813,859 common shares and 202.0582 shares of Series B Preferred Stock into 2,020,582 common shares, bringing its total holdings to 14,134,481 shares.
-
Ownership Rises to 83.9%
Post-conversion, DEFJ owns 83.9% of Transcode's outstanding common stock, based on 3,017,306 shares outstanding as of July 23, 2026, plus the newly issued conversion shares.
-
Governance Change: 60-Day Notice Removed
The Second Amended and Restated Certificate of Designation eliminated the 60-day notice requirement for waiving the beneficial ownership limitation, effective immediately upon filing on August 3, 2026.
-
Prior Disclosure Context
This conversion follows the July 27, 2026 Schedule 13D/A in which DEFJ announced its intent to waive the ownership cap and convert preferred stock, and the July 20, 2026 shareholder approval of the conversion.
Analysis · RNAZ · Life Sciences
DEFJ, the investment vehicle of CK Life Sciences, has converted all its Series A and B preferred stock into common shares, giving it 83.9% ownership of Transcode. This follows the July 27 waiver of the ownership cap and removes the 60-day notice period for future cap waivers. The conversion solidifies DEFJ's absolute control over the company, which is critical given Transcode's recent going-concern warning, Nasdaq deficiency notice, and need for shareholder approval of highly dilutive proposals. The move eliminates the preferred overhang but creates a single controlling shareholder, potentially limiting minority shareholder influence.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 43.2% of the 271 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.30%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RNAZ was trading at $4.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.9M. The 52-week trading range was $3.82 to $20.99. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.